China National Pharmaceutical Group Corporation (Sinopharm, HKG: 1099) has announced a strategic partnership with Harbin Institute of Technology, aimed at strengthening scientific and technological exchanges. The collaboration focuses on high-level national priorities, including accelerating self-reliance and self-improvement in high-level science and technology, serving the country’s rejuvenation through science and education, strengthening talent, and building a healthy China.
In-Depth Industry-University Research Cooperation
Under the agreement, both parties will engage in in-depth industry-university research cooperation. This will involve talent exchanges, scientific and technological breakthroughs, product research and development, and the translation of research into viable products, contributing to the promotion of high-quality development in the biomedical industry.
Joint Initiatives and Objectives
The partnership will see the joint construction of a national innovation platform, cooperation in the development of new products and technologies, and the strengthening of the cultivation and exchange of scientific and technological talents. Together, they will promote the deep integration and collaborative innovation of the innovation chain, industry chain, and talent chain. The financial details of this agreement have not been disclosed.-Fineline Info & Tech
